Literature DB >> 10928875

Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients.

E Morelon, M Stern, H Kreis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10928875     DOI： 10.1056/NEJM200007203430317

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

Review 1.  Stress responses affecting homeostasis of the alveolar capillary unit.

Authors:  Rubin M Tuder; Toshinori Yoshida
Journal:  Proc Am Thorac Soc       Date:  2011-11

2.  Interstitial pneumonitis is a frequent complication in liver transplant recipients treated with sirolimus.

Authors:  A Morcos; S Nair; M P Keane; N G McElvaney; P A McCormick
Journal:  Ir J Med Sci       Date:  2012-01-15       Impact factor: 1.568

3.  Comprehensive lung injury pathology induced by mTOR inhibitors.

Authors:  Guadalupe Aparicio; Moisés B Calvo; Vanessa Medina; Ovidio Fernández; Paula Jiménez; Martina Lema; Angélica Figueroa; Luis M Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2009-08       Impact factor: 3.405

4.  Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres.

Authors:  Philipp Ivanyi; Thomas Fuehner; Meike Adam; Christian Eichelberg; Edwin Herrmann; Axel Stuart Merseburger; Arnold Ganser; Viktor Grünwald
Journal:  Med Oncol       Date:  2014-08-15       Impact factor: 3.064

Review 5.  Benefit-risk assessment of sirolimus in renal transplantation.

Authors:  Dirk R J Kuypers
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients.

Authors:  Jean-Baptiste Woillard; Nassim Kamar; Annick Rousseau; Lionel Rostaing; Pierre Marquet; Nicolas Picard
Journal:  Pharmacogenet Genomics       Date:  2012-10       Impact factor: 2.089

8.  Nanotechnological Approaches to Immunosuppression and Tolerance Induction.

Authors:  Kunal Patel; Carl Atkinson; Danh Tran; Satish N Nadig
Journal:  Curr Transplant Rep       Date:  2017-04-17

9.  Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models.

Authors:  Sevdican Üstün; Caroline Lassnig; Andrea Preitschopf; Mario Mikula; Mathias Müller; Markus Hengstschläger; Thomas Weichhart
Journal:  Transpl Immunol       Date:  2015-06-11       Impact factor: 1.708

Review 10.  Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients.

Authors:  Eric Thervet; Frank Martinez; Christophe Legendre
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.